The UK and US have established a key commercial pact that will ensure zero levies on British drug shipments entering the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost spending on pharmaceuticals through the NHS. This move guarantees that import taxes on these vital goods will remain at zero for a duration of three years.
This agreement is in response to previous statements to significantly raise import taxes on branded drug products, with potential rates mentioned up to 100%.
"This agreement between the United Kingdom bolsters the international landscape for innovative medicines and establishes much-needed balance to transatlantic medicine commerce," a release said.
Trade Importance
Pharmaceuticals constitute one of the UK's most significant exports to the America, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to September, the UK shipped pharmaceutical products valued at billions to the US. This value represented a significant portion of British export trade in that span.
"This guarantee protects employment, stimulates investment and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary stated.
Key UK Commitments
The agreement involves several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to double total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, refunds were more than 20%.
Recent Tensions
This agreement follows a long-running tension between the sector and the UK government over spending levels and NHS adoption.
These tensions were heightened by claims that US patients were paying significantly more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been delayed or cancelled, while major funding commitments have been directed toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on medicines, noting that its expenditure on drugs had declined as a percentage of its total funding over the previous ten-year period.
